Kura Oncology WKN: A143UH ISIN: US50127T1097 Kürzel: KUR Branche: Chemie/Pharma

Kurs zur KURA ONCOLOGY DL-,0001 Aktie
11,90 EUR
±0,00 %±0,00
21. May, 12:59:14 Uhr, Lang & Schwarz
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
k.A. % HL Intervall: k.A. High: k.A. Low: k.A. Börse: k.A.
Anzeige
Alles ab 0 Euro pro Order. Dauerhaft.
Smartbroker
Summer.76
Summer.76, 05.08.2021 22:31
Kura Oncology Reports Second Quarter 2021 Financial Results https://www.globenewswire.com/news-release/2021/08/05/2276004/35186/en/Kura-Oncology-Reports-Second-Quarter-2021-Financial-Results.html – First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead development candidate in next-generation farnesyl transferase inhibitor program – – $567.5 million in cash, cash equivalents and investments provide runway into 2024 – ...
Summer.76
Summer.76, 06.07.2021 15:48
Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma https://www.gurufocus.com/news/1468895/kura-oncology-announces-clinical-collaboration-to-evaluate-tipifarnib-in-combination-with-alpelisib-in-head-and-neck-squamous-cell-carcinoma
Summer.76
Summer.76, 24.06.2021 14:46
Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539 https://www.globenewswire.com/news-release/2021/06/24/2252605/35186/en/Kura-Oncology-Doses-First-Patient-in-Phase-1b-Expansion-Cohorts-with-Menin-Inhibitor-KO-539.html – Phase 1b expansion cohorts designed to enable refinement of recommended Phase 2 dose – – At least 12 patients to be enrolled in each of two Phase 1b expansion cohorts: a 200 mg dose cohort and a 600 mg dose cohort – – Each cohort to be genetically enriched with NPM1-mutant and KMT2A-rearranged relapsed/refractory AML patients – – Company anticipates that patient data from the recommended Phase 2 dose cohort will be included as part of the registration-directed portion of the trial –
Summer.76
Summer.76, 22.03.2021 21:35
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology https://www.globenewswire.com/news-release/2021/03/22/2197210/0/en/Kura-Oncology-Announces-Publication-of-Tipifarnib-Phase-2-Data-in-Journal-of-Clinical-Oncology.html – Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS compared with median PFS of 3.6 months on last prior therapy (p=0.0012) – – Safety profile consistent with previously published data for tipifarnib – – Results support continuation of AIM-HN registration-directed trial in HRAS mutant HNSCC – ...
Summer.76
Summer.76, 24.02.2021 13:31
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results https://www.globenewswire.com/news-release/2021/02/24/2181292/0/en/Kura-Oncology-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results.html -  Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a wide therapeutic window in dose escalation; protocol amendment to include genetically enriched Phase 1 expansion cohorts – – Tipifarnib receives Breakthrough Therapy Designation from FDA – – $633.3 million in cash, cash equivalents and investments provide runway into 2024 – Management to host webcast and conference call today at 8:00 a.m. ET –    ....
Summer.76
Summer.76, 24.02.2021 13:21
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma http://www.globenewswire.com/news-release/2021/02/24/2181242/0/en/Kura-Oncology-Receives-FDA-Breakthrough-Therapy-Designation-for-Tipifarnib-in-Head-and-Neck-Squamous-Cell-Carcinoma.html ...today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma (HNSCC) with variant allele frequency ≥ 20% after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial (AIM-HN) in this indication of high unmet need.  ...
Summer.76
Summer.76, 08.01.2021 22:39
Kura teams up with Illumina for a companion diagnostic for lead therapy https://seekingalpha.com/news/3650072-kura-teams-up-illumina-for-companion-diagnostic-for-lead-therapy In a regulatory filing, Kura Oncology (NASDAQ:KURA) announces that on January 04, it entered into a collaboration agreement, with Illumina (NASDAQ:ILMN) for a companion diagnostic test for use with the company’s lead product candidate, tipifarnib. The agreement tided to a project schedule will require Illumina to develop and commercialize an assay as a companion diagnostic test for use with tipifarnib to identify head and neck squamous cell carcinoma (‘HNSCC”) patients with an HRAS mutation. The collaboration covers the United States, the United Kingdom, major European markets, and other countries as mutually agreed by the two parties. Currently, Kura is advancing a global, multi-center, open-label, non-comparative registration-directed clinical trial of tipifarnib in HRAS mutant HNSCC.
Summer.76
Summer.76, 11.12.2020 22:33
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares https://www.globenewswire.com/news-release/2020/12/11/2144046/0/en/Kura-Oncology-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Option-to-Purchase-Additional-Shares.html
Summer.76
Summer.76, 10.12.2020 19:50
https://seekingalpha.com/article/4394095-kura-oncology-advanced-precision-medicine-opportunity-excites-not-without-risks
Summer.76
Summer.76, 09.12.2020 11:17
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock https://www.globenewswire.com/news-release/2020/12/09/2141845/0/en/Kura-Oncology-Announces-Pricing-of-300-Million-Public-Offering-of-Common-Stock.html ...at a price to the public of $37.00 per share. 
Kommentare
1 KURA ONCOLOGY DL-,0001 Hauptdiskussion
Kursdetails
Geld (bid) 11,80 (419)
Brief (ask/offer) 12,00 (419)
Spread 1,67
Geh. Stück 0
Eröffnung 11,90
Vortag 11,90
Tageshoch 11,90
Tagestief 11,90
52W Hoch 21,20
52W Tief 10,00
Tagesvolumen
in EUR gehandelt 0 Stk
in USD gehandelt 676 Tsd. Stk
Gesamt 676 Tsd. Stk
Anzeige
Smartbroker
Der Broker von Deutschlands größter Finanzcommunity
Geld/Brief Kurse
Börse Geld Brief Zeit Volumen Kurs
Frankfurt 11,90 12,00 1653026578 20. May 11,40 EUR
Düsseldorf 11,60 12,20 1653067881 20. May 11,10 EUR
Stuttgart 11,80 12,00 1653043894 20. May 11,50 EUR
Nasdaq 12,58 12,59 1653091200 02:00 675.696 Stk 12,59 USD
AMEX 1653091200 02:00 100 Stk 12,58 USD
Tradegate 11,70 12,10 1653078430 20. May 11,90 EUR
Lang & Schwarz 11,80 12,00 1653130754 12:59 11,90 EUR
London 1652804183 17. May 12,06 USD
TTMzero RT 1653076802 20. May 11,90 EUR
ges. 675.796 Stk
Realtime / Verzögert
Börsennotierung
Marktkapitalisierung in EUR
779,6 Mio.
Anzahl der Aktien
66,6 Mio.
Termine
Aktionärsstruktur %
Freefloat 0,00
0,00
Grundlegende Daten zur KURA ONCOLOGY DL-,0001 Aktie
Finanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
KUV - - - - - - -
Ergebnis je Aktie (bereinigt) - - - - - - -
Cashflow - - - - - - -
Eigenkapitalquote - - - - - - -
Verschuldungsgrad - - - - - - -
Eigenkapitalrendite - - - - - - -
Gesamtkapitalrendite - - - - - - -
EBITDA - - - - - - -
EBIT - - - - - - -
Fundamentaldaten 2018 2019 2020 2021 2022e 2023e 2024e
KCV - - - - - - -
Dividendenrendite - - - - - - -
Kurs-Gewinn-Verhältnis (KGV) - - - - - - -
Dividende je Aktie - - - - - - -
Bilanzdaten 2018 2019 2020 2021 2022e 2023e 2024e
Netto-Provisionsüberschuss - - - - - - -
Umsatzerlöse - - - - - - -
Ergebnis vor Steuern - - - - - - -
Steuern - - - - - - -
Ausschüttungssumme - - - - - - -
Nettoverzinsung - - - - - - -
Zinsertrag - - - - - - -
Gesamtertrag - - - - - - -